AstraZeneca–BMS Merger Report Sends Shares Tumbling Into Antitrust Spotlight

The Reported AstraZeneca–Bristol Myers Merger Talks, Explained

Shares in AstraZeneca fell more than 6% on Monday after the Financial Times reported that the British drugmaker had held very preliminary talks with US rival Bristol Myers Squibb (BMS) about a possible combination. The drop wiped more than £13 billion (about €15 billion) off AstraZeneca's market value at one point, while BMS shares rose roughly 5% in premarket trading.

The two companies have not confirmed the report. AstraZeneca declined to comment, and people described as close to the company said only that very preliminary considerations about combining the two research-heavy drugmakers had been discussed. A tie-up on the scale reported would create one of the largest pharmaceutical groups in the world, with a combined market value of nearly $400 billion (around €350 billion) — placing it behind only Eli Lilly and Johnson & Johnson among global pharma companies.

Investors and analysts responded with open skepticism. Markus Manns, a portfolio manager at Union Investment, an AstraZeneca shareholder, said a merger with BMS is neither strategically nor financially sensible, adding that many past pharma megamergers destroyed value. Michael Leuchten of Jefferies said he was somewhat perplexed by the report. The negative reaction matters because AstraZeneca had built its recent investment case on organic growth: CEO Pascal Soriot has publicly ruled out large takeovers and set a revenue target of $80 billion by 2030, with sales reaching nearly $60 billion in the last fiscal year and rising 6% on a currency-adjusted basis in the first half of 2026.

Any deal would face serious regulatory hurdles. The two groups overlap heavily in oncology, which accounted for about 44% of AstraZeneca's revenue, and US competition authorities would probably examine the transaction under the FTC. Analysts expect that antitrust approval, if granted at all, would come with demands to sell significant business units.

Why Investors Balked — and Where Regulators Could Intervene

Why the market punished AstraZeneca, not BMS

The share-price reaction tells you which side investors think needed this deal. BMS gained because a takeover by a larger, faster-growing partner would offer an exit from a troubled patent outlook. AstraZeneca lost value because the report forced shareholders to contemplate paying for that distress. Union Investment's reaction is particularly important: it is an AstraZeneca shareholder and says the logic does not hold. The market is effectively pricing in a risk that management reverses its stated no-M&A strategy for a deal whose synergies are unclear.

What BMS would bring — and what it needs

BMS has spent heavily to rebuild its portfolio, including the $74 billion acquisition of Celgene in 2019 and the $14 billion purchase of Karuna two years ago. Those deals helped offset declining sales of the cancer drug Revlimid, which now faces generic competition, and the company last week beat expectations and raised its full-year sales forecast. But the bigger problem is still ahead: patents on the blood thinner Eliquis and the cancer drug Opdivo are set to expire in the coming years, and those two products still generate more than half of BMS revenue. That makes BMS a motivated partner, and helps explain why its shares rose on the prospect of a takeover despite some skepticism about AstraZeneca.

Where the antitrust case would get complicated

The most obvious obstacle is oncology. Cancer drugs account for roughly 44% of AstraZeneca's revenue and are also a core part of BMS's portfolio, so a combined company would hold a strong position in several treatment categories. The FTC, which must approve the deal, may demand divestitures of overlapping assets. The political backdrop is mixed: under President Donald Trump, US antitrust enforcement has generally been more permissive toward mergers, but regulators could be sensitive to a foreign company absorbing one of America's largest drugmakers. BMS is a US group; AstraZeneca is British. That national sensitivity, combined with patient and pricing-policy concerns, makes regulatory approval the central risk rather than a side issue.

The strategic question for AstraZeneca

Soriot has repeatedly said AstraZeneca can reach its $80 billion revenue goal without acquisitions. The company's pipeline is unusually deep — nearly two dozen drugs in late-stage trials — and its first-half 2026 growth of 6% is consistent with that story. Why, then, would it consider a merger with a company facing patent cliffs? One possible rationale is speed in the US, where AstraZeneca already employs about a fifth of its nearly 100,000 staff and plans double-digit-billion investments. BMS would bring US commercial infrastructure and complementary cardiovascular and immunology franchises. But the reported numbers suggest AstraZeneca, at roughly twice BMS's market value, would be the acquirer in substance and would bear most of the integration and antitrust risk. That is the calculation the market made on Monday — and it came out negative.

What Investors Should Watch as the AstraZeneca–BMS Story Develops

• Look for an official statement. AstraZeneca and BMS have not confirmed the FT report. A confirmation would trigger a detailed antitrust review; a denial would probably reverse much of Monday's share-price move in both stocks.
• Track the FTC rather than deal speculation. Oncology overlap — about 44% of AstraZeneca's sales — makes divestitures the most likely condition, and any formal filing will disclose how much overlap the companies admit.
• For BMS shareholders, the due date matters more than the headlines: Eliquis and Opdivo patent expiries in the coming years threaten more than half of BMS revenue. Deal terms will need to compensate AstraZeneca for taking on that gap.
• For AstraZeneca shareholders, weigh any deal against management's own benchmark: Soriot's $80 billion revenue target for 2030, built without M&A, and first-half 2026 currency-adjusted growth of 6%. A transaction that undermines that story is unlikely to win investor support.
• Watch BMS's own shares as a tell: they have risen more than 20% since the start of the year but remain below their level of five years ago — which suggests the market is still pricing in execution risk, not a certain takeover premium.